William N Hait

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. doi request reprint Anticancer drug development: the grand challenges
    William N Hait
    Ortho Biotech Oncology Research and Development, 920 Route 202, Raritan, New Jersey 08869, USA
    Nat Rev Drug Discov 9:253-4. 2010
  2. doi request reprint Forty years of translational cancer research
    William N Hait
    Janssen, The Pharmaceutical Companies of Johnson and Johnson, Raritan, NJ 08869, USA
    Cancer Discov 1:383-90. 2011
  3. doi request reprint Targeted cancer therapeutics
    William N Hait
    Division of Johnson and Johnson, Ortho Biotech Oncology Research and Development, Raritan, New Jersey 08869, USA
    Cancer Res 69:1263-7; discussion 1267. 2009
  4. doi request reprint AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development
    Samir N Khleif
    National Cancer Institute, Raritan, New Jersey, USA
    Clin Cancer Res 16:3299-318. 2010

Collaborators

Detail Information

Publications4

  1. doi request reprint Anticancer drug development: the grand challenges
    William N Hait
    Ortho Biotech Oncology Research and Development, 920 Route 202, Raritan, New Jersey 08869, USA
    Nat Rev Drug Discov 9:253-4. 2010
    ..What are the key challenges in anticancer drug development, and how might they be addressed?..
  2. doi request reprint Forty years of translational cancer research
    William N Hait
    Janssen, The Pharmaceutical Companies of Johnson and Johnson, Raritan, NJ 08869, USA
    Cancer Discov 1:383-90. 2011
    ....
  3. doi request reprint Targeted cancer therapeutics
    William N Hait
    Division of Johnson and Johnson, Ortho Biotech Oncology Research and Development, Raritan, New Jersey 08869, USA
    Cancer Res 69:1263-7; discussion 1267. 2009
    ..Finally, a detailed understanding of the target's structure and function will help anticipate and identify mechanism of drug resistance and help design drugs and combinations of drugs that retain activity...
  4. doi request reprint AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development
    Samir N Khleif
    National Cancer Institute, Raritan, New Jersey, USA
    Clin Cancer Res 16:3299-318. 2010
    ....